$-0.69 EPS Expected for Clearside BioMedical, Inc. (CLSD); Flotek Industries Del (FTK) Shorts Down By 8.8%

February 13, 2018 - By Darrin Black

Analysts expect Clearside BioMedical, Inc. (NASDAQ:CLSD) to report $-0.69 EPS on March, 13.They anticipate $0.24 EPS change or 53.33% from last quarter’s $-0.45 EPS. After having $-0.72 EPS previously, Clearside BioMedical, Inc.’s analysts see -4.17% EPS growth. The stock increased 2.43% or $0.14 during the last trading session, reaching $5.89. About 86,626 shares traded. Clearside BioMedical, Inc. (NASDAQ:CLSD) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Flotek Industries Incorporated Del (NYSE:FTK) had a decrease of 8.8% in short interest. FTK’s SI was 10.35M shares in February as released by FINRA. Its down 8.8% from 11.35M shares previously. With 977,400 avg volume, 11 days are for Flotek Industries Incorporated Del (NYSE:FTK)’s short sellers to cover FTK’s short positions. The SI to Flotek Industries Incorporated Del’s float is 22.88%. The stock decreased 0.80% or $0.04 during the last trading session, reaching $4.95. About 102,115 shares traded. Flotek Industries, Inc. (NYSE:FTK) has declined 6.33% since February 13, 2017 and is downtrending. It has underperformed by 23.03% the S&P500.

Investors sentiment increased to 1.84 in 2017 Q3. Its up 0.59, from 1.25 in 2017Q2. It is positive, as 21 investors sold Flotek Industries, Inc. shares while 23 reduced holdings. 30 funds opened positions while 51 raised stakes. 47.40 million shares or 14.16% less from 55.22 million shares in 2017Q2 were reported. Moreover, Creative Planning has 0% invested in Flotek Industries, Inc. (NYSE:FTK) for 120,778 shares. Thrivent Financial For Lutherans holds 35,090 shares. D E Shaw invested in 0% or 354,070 shares. The Massachusetts-based Boston has invested 0.01% in Flotek Industries, Inc. (NYSE:FTK). 1.56 million were accumulated by Northpointe Ltd Limited Liability Company. Prelude Capital Ltd Liability Company invested 0.01% of its portfolio in Flotek Industries, Inc. (NYSE:FTK). Minnesota-based Us Savings Bank De has invested 0% in Flotek Industries, Inc. (NYSE:FTK). Gru owns 44,059 shares for 0% of their portfolio. Barclays Public Ltd Company invested in 0% or 53,360 shares. Ubs Asset Management Americas Inc invested in 23,429 shares or 0% of the stock. Moreover, Nbw Capital has 0.33% invested in Flotek Industries, Inc. (NYSE:FTK) for 260,552 shares. Northern Trust has 0% invested in Flotek Industries, Inc. (NYSE:FTK) for 683,551 shares. Pnc Ser Group has invested 0% in Flotek Industries, Inc. (NYSE:FTK). Morgan Stanley stated it has 0% of its portfolio in Flotek Industries, Inc. (NYSE:FTK). State Bank Of America Corp De holds 85,374 shares.

Among 6 analysts covering Flotek Industries (NYSE:FTK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Flotek Industries had 11 analyst reports since July 27, 2015 according to SRatingsIntel. Vetr downgraded it to “Strong-Buy” rating and $20.11 target in Friday, August 28 report. The firm earned “Buy” rating on Tuesday, September 22 by Vetr. The rating was maintained by Seaport Global with “Buy” on Wednesday, January 17. Oppenheimer upgraded the stock to “Perform” rating in Monday, July 27 report. The stock of Flotek Industries, Inc. (NYSE:FTK) earned “Buy” rating by Vetr on Thursday, August 6. The rating was initiated by KLR Group on Monday, December 14 with “Buy”. Oppenheimer maintained the stock with “Perform” rating in Wednesday, October 7 report. The firm has “Speculative Buy” rating by Seaport Global Securities given on Wednesday, January 20.

Flotek Industries, Inc. develops and supplies chemistry and services to the gas and oil industries in the United States and internationally. The company has market cap of $281.29 million. It operates through two divisions, Energy Chemistry Technologies and Consumer and Industrial Chemistry Technologies. It currently has negative earnings. The Energy Chemistry Technologies segment is involved in the design, development, manufacture, packaging, and marketing of chemistries under the Complex nano-Fluid brand name for use in gas and oil well drilling, cementing, completion, stimulation, and production activities, as well as for use in enhanced and improved oil recovery markets.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. The company has market cap of $149.27 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion ; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). It currently has negative earnings. The company's pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: